2025 China Biobanking Market Revenue Opportunities Report
Description
The 2025 China Biobanking Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biobanking Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biobanking market in China include Shanghai Zhangjiang Biobank, Thermo Fisher Scientific Inc., Merck KGaA, and BD (Becton Dickinson & Co.). Shanghai Zhangjiang Biobank, based in Shanghai's Zhangjiang Science City, is a major Chinese commercial biobank targeting a capacity of 10 million human-derived samples and has developed Chinese FDA-approved products, including a liver cancer early diagnosis kit. Thermo Fisher Scientific offers a broad range of biobank solutions such as instruments, software, and sample management systems, supporting scientific research globally and within China. Merck KGaA provides comprehensive biobanking tools like laboratory equipment and reagents, supporting innovative research with a focus on sample collection and storage. BD, with a legacy in medical technology, offers advanced biobanking solutions that facilitate precision medicine and personalized healthcare.
These companies contribute significantly to the China biobank market, which generated USD 5.765 billion in 2023 and is forecasted to grow at a CAGR of 10.1% through 2030. The market is characterized by a rapid increase in biobanking capabilities supported by government funding, private investment, and technological advancements. Shanghai Zhangjiang Biobank emphasizes integration with genomics and proteomics platforms for quick R&D translation. Thermo Fisher and Merck leverage their global expertise to enhance local biobanking infrastructure, while BD focuses on end-to-end specimen processing and analysis. Together, they drive growth and innovation in China’s biobanking sector, reflecting the country’s ambition to become a leader in biotechnology and precision medicine.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biobanking Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biobanking market in China include Shanghai Zhangjiang Biobank, Thermo Fisher Scientific Inc., Merck KGaA, and BD (Becton Dickinson & Co.). Shanghai Zhangjiang Biobank, based in Shanghai's Zhangjiang Science City, is a major Chinese commercial biobank targeting a capacity of 10 million human-derived samples and has developed Chinese FDA-approved products, including a liver cancer early diagnosis kit. Thermo Fisher Scientific offers a broad range of biobank solutions such as instruments, software, and sample management systems, supporting scientific research globally and within China. Merck KGaA provides comprehensive biobanking tools like laboratory equipment and reagents, supporting innovative research with a focus on sample collection and storage. BD, with a legacy in medical technology, offers advanced biobanking solutions that facilitate precision medicine and personalized healthcare.
These companies contribute significantly to the China biobank market, which generated USD 5.765 billion in 2023 and is forecasted to grow at a CAGR of 10.1% through 2030. The market is characterized by a rapid increase in biobanking capabilities supported by government funding, private investment, and technological advancements. Shanghai Zhangjiang Biobank emphasizes integration with genomics and proteomics platforms for quick R&D translation. Thermo Fisher and Merck leverage their global expertise to enhance local biobanking infrastructure, while BD focuses on end-to-end specimen processing and analysis. Together, they drive growth and innovation in China’s biobanking sector, reflecting the country’s ambition to become a leader in biotechnology and precision medicine.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
